Please login to the form below

Not currently logged in
Email:
Password:

non-alcoholic steatohepatitis drugs

This page shows the latest non-alcoholic steatohepatitis drugs news and features for those working in and with pharma, biotech and healthcare.

Allergan buys two NASH drug developers in one day

Allergan buys two NASH drug developers in one day

Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH) drug developers Tobira Therapeutics and Akarna Therapeutics. ... pipeline. The acquisition puts Allergan in a race to market with

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics